The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Objective. This study was carried out to investigate the influence of CYP3A induction with rifampicin on imatinib (Gleevec) exposure. Methods. The study employed a single center, single-sequence design. A group of 14 healthy male and female subjects received imatinib as a single 400mg oral dose on two occasions: on study day1 and on study day15. Rifampicin treatment (600mg once daily) for CYP4503A...